Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
ASCO 2025 preview – late-breakers in focus
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
Protagonist Verifies Takeda’s interest
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
